Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817985 | 0.88 | FAAH (0.39) | DPP4DPP7DPP8DPP9PREP | |
| SCHEMBL8264016 | 0.78 | — | — | |
| SCHEMBL10608520 | 0.77 | DPP4 (0.39) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL10611575 | 0.77 | DPP4 (0.47) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL23518518 | 0.77 | ALDH1A1 (0.42) | DPP4 | |
| SCHEMBL9946326 | 0.74 | DPP4 (0.47) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL4160072 | 0.74 | — | — | |
| SCHEMBL5069160 | 0.74 | — | — | |
| SCHEMBL6052795 | 0.74 | — | — | |
| SCHEMBL11339373 | 0.74 | DPP4 (0.42) | DPP4DPP7DPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045771-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS | Cadila Corporated Campus (IN) | 2014-02-13 | — | — | US | disclosed |
| US-8563517-B2 | Dipeptidyl peptidase IV (DP-IV) compounds | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-20110183919-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS | CADILA PHARMACEUTICALS LTD. (IN) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045771-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 6/4885 |
| US-20110183919-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 6/4885 |
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.